Table 1.
Treatment of HCV in HIV-coinfected persons*
| Genotype | Patients | Study | Medications | Duration (weeks) |
N | SVR12 (%) | Ref |
|---|---|---|---|---|---|---|---|
| 1 or 41 | TN | ION4 | LDV/SOF | 12 | 335 | 96 | 56 |
| 1 | TN | NIH | LDV/SOF | 12 | 50 | 98 | 55 |
| 1 | TN + TE | TURQUOISE-1 | OPrD RBV | 12 | 31 | 94 | 57 |
| 1 | TN + TE | TURQUOISE-1 | OPrD RBV | 24 | 32 | 91 | 57 |
| 1 | TN | ALLY-2 | DCV/SOF | 12 | 83 | 96 | 59 |
| 1 | TN | ALLY-2 | DCV/SOF | 8 | 41 | 76 | 59 |
| 1 | TE | ALLY-2 | DCV/SOF | 12 | 44 | 98 | 59 |
| 2 | TN | PHOTON 1+2 | SOF + RBV | 12 | 45 | 89 | 58, 61 |
| 2 | TE | PHOTON 1+2 | SOF + RBV | 24 | 30 | 90 | 58, 61 |
| 3 | TN | PHOTON 1+2 | SOF + RBV | 12 | 42 | 67 | 58, 61 |
| 3 | TN | PHOTON 1+2 | SOF + RBV | 24 | 57 | 91 | 58, 61 |
| 3 | TE | PHOTON 1+2 | SOF + RBV | 24 | 66 | 88 | 58, 61 |
| 3 | TN + TE | ALLY-2 | DCV/SOF | 12 | 10 | 100 | 59 |
| 4 | TN | PHOTON 1+2 | SOF + RBV | 24 | 31 | 84 | 58, 61 |
*
TN = treatment naïve; TE = treatment experienced; LDV = ledipasvir 90mg; SOF= sofosbuvir 400 mg; OPrD = ombitasvir, paritaprevir, ritonavir, and dasabuvir; RBV=weight-based ribavirin; DCV = daclatasvir
1
8 persons had genotype 4 and all had SVR12